About Stiefel
Stiefel is a Healthcare company based in Durham (United States) founded in 1847, and was acquired by GSK in April 2009. Dermatology prescription products are manufactured and marketed globally. Stiefel has completed 2 acquisitions, including Barrier Therapeutics and Connetics Corporation. Its Indian entity Gsk Pharma India Private Limited reported revenue of ₹31.87 Cr. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its competitors include Revance Therapeutics, Castle Creek Pharma and Dermavant; 3 of its 3 listed competitors have raised funding.
Company details
Stiefel, a subsidiary of GSK, was founded in 1847 and is headquartered in Durham, United States. Operations focus on the dermatology sector, where prescription products for various skin conditions are manufactured and marketed worldwide. A portfolio of seven such products is maintained, supporting advancements in skin science. As the largest independent dermatology company, global reach is emphasized in its activities.
- Headquarters Durham, United States
- Stage Acquired
- SectorsHealthcare
- Website stiefel.com
- Social LinkedIn X Facebook
- Acquired by GSK (Apr 2009)
- Legal Name Gsk Pharma India Private Limited
- Date of Incorporation 02 Jun, 2000
- Indian entity revenue₹31.87 Cr
FY 2025 · +49% YoY
- Indian entity net profit₹2.26 Cr
FY 2025 · 7% margin
- Indian entity EBITDA₹3.42 Cr
FY 2025 · 11% margin
- Investors
- Investments & AcquisitionsBarrier Therapeutics
& 1 more
- Acquired byGSK
(Apr 2009)
Associated legal entities of Stiefel
Stiefel operates through Gsk Pharma India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Gsk Pharma India Private Limited CIN U24239MH2000PTC126937 | Active | 02 Jun 2000 | Mumbai, Maharashtra | ₹31.9 Cr | 2 | View details |
Investors in Stiefel
Stiefel has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom |
Investor details for Stiefel
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Gsk Pharma India Private Limited (Stiefel)
Gsk Pharma India Private Limited is the primary company behind Stiefel. The board of Gsk Pharma India Private Limited currently have 2 directors; the longest-serving is Ajay Avinash Nadkarni, appointed in 2011. 15 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Ajay Avinash Nadkarni DIN 03319418 | Director | 03 Jan 2011 | 15 yrs 9 mo | Gsk Pharma India Private Limited |
| Ayush Kumar DIN 10462441 | Director | 15 Jan 2024 | 2 yrs 9 mo | Gsk Pharma India Private Limited |
People of Stiefel
5 people are tracked at Stiefel (2 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Richard Ho | CEO | Leadership |
Jim Keith | Senior Director Trade Sales | Leadership |
Laura Timms | Senior Territory Manager | Team |
Adrian Gonzalez | Senior Sales Representative | Team |
Mayra Veloz | Executive Sales Rep. | Team |
Complete people profiles for Stiefel
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Stiefel
Figures of Gsk Pharma India Private Limited, the primary company behind Stiefel, for FY 2025. Revenue was ₹31.87 Cr (+49% year on year). Net profit was ₹2.26 Cr (7% margin). EBITDA was ₹3.42 Cr (11% margin). Revenue has grown at a compounded annual rate of +34% over three years and +4% over five years.
- ₹31.87 CrRevenue · FY 2025 · +49% YoY
- ₹2.26 CrNet profit · 7% margin
- ₹3.42 CrEBITDA · 11% margin
- ₹7.68 CrPaid-up capital
- +34%Revenue CAGR, 3 years
- +4%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Gsk Pharma India Private Limited are on its company page.
Detailed financial statements for Stiefel
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stiefel
Stiefel has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Barrier Therapeutics and Connetics Corporation.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Topical drugs for dermatology disorders were developed. | barriertherapeutics.com | Princeton, United States | 2002 | Jun 2008 | $148M | |
Biopharmaceutical medicines are developed and distributed globally by the company. | connetics.com | Palo Alto, United States | 1993 | Oct 2006 | $640M |
Complete acquisition details for Stiefel
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Stiefel
4 dated milestones of Stiefel across 162 years, from founding to its latest funding, stage changes and deals.
- Founded Stiefel is founded.
- Acquisition Acquires Connetics Corporation.
- Acquisition Acquires Barrier Therapeutics.
- Exit Acquired by GSK.
Competitors of Stiefel
Stiefel has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Dermavant.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. |
Detailed competitors of Stiefel
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Stiefel
Websites that share an audience with Stiefel (stiefel.com).
Websites whose visitors overlap most with Stiefel. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fibrogen.com | 100% | 6.2K | #2,827,257 | View details | |
| biospecifics.com | 95% | View details | |||
| renovo.com | 85% | View details | |||
kospharm.com | kospharm.com | 84% | – | ||
| galderma.com | 62% | 164.6K | #278,436 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Stiefel
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as Stiefel (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stiefel
Complete news archive for Stiefel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stiefel
Stiefel was founded in 1847.
Stiefel is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
The primary company behind Stiefel, Gsk Pharma India Private Limited, reported revenue of ₹31.87 Cr for FY 2025, up 49% year on year.
Stiefel, a subsidiary of GSK, was founded in 1847 and is headquartered in Durham, United States. Operations focus on the dermatology sector, where prescription products for various skin conditions are manufactured and marketed worldwide. A portfolio of seven such products is maintained, supporting advancements in skin science. As the largest independent dermatology company, global reach is emphasized in its activities.
Stiefel's top competitors include Revance Therapeutics, Dermavant and Castle Creek Pharma.
Stiefel has made 2 acquisitions, including Barrier Therapeutics, and Connetics Corporation.
Stiefel has 1 investor. Key investors include GSK.
Stiefel operates through Gsk Pharma India Private Limited.
Yes. Stiefel was acquired by GSK in April 2009.
The legal entities of Stiefel currently have 2 directors, including Ayush Kumar, Ajay Avinash Nadkarni.